Helena Schäfer

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak

P. Willeit, H. Winner, D. von Laer, 2022, Frontiers in Public Health.

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria

P. Willeit, D. von Laer, Z. Bánki, 2022, Viruses.

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

A. Sette, H. Ulmer, V. Simon, 2022, eBioMedicine.

High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz

D. von Laer, B. Falkensammer, W. Borena, 2022, Viruses.

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

D. von Laer, B. Falkensammer, W. Borena, 2022, Nature communications.

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial

K. Becker, P. Willeit, L. Forer, 2023, The Lancet. Microbe.